CytomX starts dosing in Phase I/II trial of CX-2009 to treat solid tumours

US-based biopharmaceutical firm CytomX Therapeutics has started dosing patients in a Phase I/II clinical trial (PROCLAIM CX-2009) of CX-2009 for the treatment of patients with select advanced solid tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news